Search the collection

Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 1
ArticlesPeer ReviewedFull Text
Determining Susceptibility and Potential Mediators of Resistance for the Novel Polymyxin Derivative, SPR206, in Acinetobacter baumannii
Author / Creator:Abdul-Mutakabbir, Jacinda C. ; Opoku, Nana Sakyi ; Tan, Karen K. ; Jorth, Peter ; Nizet, Victor ; Fletcher, Hansel M. ; Kaye, Keith S. ; Rybak, Michael J.
Publisher:Switzerland: MDPI AG
Journal title:Antibiotics (Basel), 2024-01, Vol.13 (1), p.47
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 2
ArticlesPeer ReviewedFull Text
2130. Safety and Pharmacokinetics of SPR206 in Subjects with Varying Degrees of Renal Impairment
Author / Creator:Bruss, Jon ; Bader, Justin C ; Hamed, Kamal
Journal title:Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 3
ArticlesPeer ReviewedFull Text
Determining Susceptibility and Potential Mediators of Resistance for the Novel Polymyxin Derivative, SPR206, in IAcinetobacter baumannii/I
Author / Creator:Abdul-Mutakabbir, Jacinda C ; Opoku, Nana Sakyi ; Tan, Karen K ; Jorth, Peter ; Nizet, Victor ; Fletcher, Hansel M ; Kaye, Keith S ; Rybak, Michael J
Publisher:MDPI AG
Journal title:Antibiotics (Basel), 2024-01, Vol.13 (1)
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 4
ArticlesPeer ReviewedFull Text
1677. In vitro Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in United States Hospitals
Author / Creator:Mendes, Rodrigo E ; Sader, Helio S ; Ryan Arends, S J ; Cotroneo, Nicole ; Critchley, Ian A ; Castanheira, Mariana
Journal title:Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 5
ArticlesPeer ReviewedFull Text
1676. Activity of SPR206 and Comparator Agents Against Pseudomonas aeruginosa and Acinetobacter baumannii Causing Infections in United States Hospitals
Author / Creator:Mendes, Rodrigo E ; Sader, Helio S ; Ryan Arends, S J ; Cotroneo, Nicole ; Critchley, Ian A ; Castanheira, Mariana
Journal title:Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 6
ArticlesPeer ReviewedFull Text
625. SPR206 Pharmacokinetics (PK) in Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) in Healthy Adult Subjects
Author / Creator:Rodvold, Keith A ; Bader, Justin ; Gupta, Vipul K ; Lister, Troy ; Srivastava, Praveen ; Bruss, Jon
Journal title:Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 7
ArticlesPeer ReviewedFull Text
1695. Combination Therapy for the Investigational Polymyxin SPR206 and Meropenem (MEM) Increases the Rapidity and Extent of Killing of Pseudomonas aeruginosa (PA) and Prevents the Bacterium from Emerg...
Author / Creator:Louie, Arnold ; Bader, Justin ; Cotroneo, Nicole ; Lister, Troy ; Liu, Weiguo ; Brown, David ; Myrick, Jenny ; Drusano, George
Journal title:Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 8
ArticlesPeer ReviewedFull Text
1295. Activity of SPR206, a Polymyxin B Derivative, Compared to Colistin Alone and in Combination Against Multidrug-Resistant Pseudomonas aeruginosa Strains
Author / Creator:Abdul-Mutakabbir, Jacinda C ; Nguyen, Logan ; Stamper, Kyle ; Maassen, Philip ; Lev, Katherine ; Morrisette, Taylor ; Kebriaei, Razieh ; Rybak, Michael J
Publisher:US: Oxford University Press
Journal title:Open forum infectious diseases, 2020-12, Vol.7 (Supplement_1), p.S662-S663
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 9
ArticlesPeer ReviewedFull Text
Next-Generation Polymyxin Class of Antibiotics: A Ray of Hope Illuminating a Dark Road
Author / Creator:Aslan, Abdullah Tarık ; Akova, Murat ; Paterson, David L.
Publisher:Switzerland: MDPI AG
Journal title:Antibiotics (Basel), 2022-11, Vol.11 (12), p.1711
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 10
Newsletter articlesFull Text
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
Publisher:New York: NASDAQ OMX Corporate Solutions, Inc
Journal title:NASDAQ OMX's News Release Distribution Channel, 2024
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 11
ArticlesFull Text
Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories
Publisher:NewsRX LLC
Journal title:Obesity, fitness, & wellness week, 2021-07, p.43
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 12
Web ResourcesFull Text
Benzinga: Spero Therapeutics Kick Starts Two SPR206 Trials For Bronchoalveolar Lavage, Renal Impairment
Author / Creator:Singh, Vandana
Publisher:Chatham: Newstex
Journal title:Newstex Finance & Accounting Blogs, 2021
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 13
Newsletter articlesFull Text
Press Release: Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
Publisher:New York: Dow Jones & Company Inc
Journal title:Dow Jones Institutional News, 2024
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 14
Newsletter articlesFull Text
Spero Therapeutics Awarded up to $23 Million by the National Institute of Allergy and Infectious Diseases to Support the Development of SPR206: The National Institute of Allergy and Infectious Disease...
Publisher:New York: NASDAQ OMX Corporate Solutions, Inc
Journal title:NASDAQ OMX's News Release Distribution Channel, 2021
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 15
Newsletter articlesFull Text
Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206: Spero grants Pfizer rights to develop, manufacture, and commercialize SPR206 in ex-U.S....
Publisher:New York: NASDAQ OMX Corporate Solutions, Inc
Journal title:NASDAQ OMX's News Release Distribution Channel, 2021
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 16
Newsletter articlesFull Text
Everest Medicines Announces Approval of Investigational New Drug Application by China NMPA for SPR206
Publisher:New York: PR Newswire Association LLC
Journal title:PR Newswire Asia, 2021
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 17
Newsletter articlesFull Text
Everest Medicines Announces Approval of Investigational New Drug Application by China NMPA for SPR206
Publisher:New York: PR Newswire Association LLC
Journal title:PR Newswire, 2021
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 18
Newsletter articlesFull Text
Press Release: Everest Medicines Announces Approval of Investigational New Drug Application by China NMPA for SPR206
Publisher:New York: Dow Jones & Company Inc
Journal title:Dow Jones Institutional News, 2021
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 19
Newsletter articlesFull Text
Everest Medicines: Spero Therapeutics, Pfizer In Deal For SPR206 In Ex-U.S. And Ex-Asia Territories
Publisher:Miami: ContentEngine LLC, a Florida limited liability company
Journal title:CE Noticias Financieras, 2021
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.
Export this record
Export to excel
Print
Export record to excel
File type to download
Beta version
Select record 20
Newsletter articlesFull Text
Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206
Publisher:Amman: Disco Digital Media, Inc
Journal title:Financial Services Monitor Worldwide, 2021
View online as a Library member
Access ebook if you are in the Library. Registered NSW residents may log in from home.

Showing 1 to 20 of 61 results

Export record to excel

Export this record

Export record to excel

Determining Susceptibility and Potential Mediators of Resistance for the Novel Polymyxin Derivative, SPR206, in Acinetobacter baumannii

Export this record

Export record to excel

2130. Safety and Pharmacokinetics of SPR206 in Subjects with Varying Degrees of Renal Impairment

Export this record

Export record to excel

Determining Susceptibility and Potential Mediators of Resistance for the Novel Polymyxin Derivative, SPR206, in IAcinetobacter baumannii/I

Export this record

Export record to excel

1677. In vitro Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in United States Hospitals

Export this record

Export record to excel

1676. Activity of SPR206 and Comparator Agents Against Pseudomonas aeruginosa and Acinetobacter baumannii Causing Infections in United States Hospitals

Export this record

Export record to excel

625. SPR206 Pharmacokinetics (PK) in Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) in Healthy Adult Subjects

Export this record

Export record to excel

1695. Combination Therapy for the Investigational Polymyxin SPR206 and Meropenem (MEM) Increases the Rapidity and Extent of Killing of Pseudomonas aeruginosa (PA) and Prevents the Bacterium from Emerg...

Export this record

Export record to excel

1295. Activity of SPR206, a Polymyxin B Derivative, Compared to Colistin Alone and in Combination Against Multidrug-Resistant Pseudomonas aeruginosa Strains

Export this record

Export record to excel

Next-Generation Polymyxin Class of Antibiotics: A Ray of Hope Illuminating a Dark Road

Export this record

Export record to excel

Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

Export this record

Export record to excel

Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories

Export this record

Export record to excel

Benzinga: Spero Therapeutics Kick Starts Two SPR206 Trials For Bronchoalveolar Lavage, Renal Impairment

Export this record

Export record to excel

Press Release: Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

Export this record

Export record to excel

Spero Therapeutics Awarded up to $23 Million by the National Institute of Allergy and Infectious Diseases to Support the Development of SPR206: The National Institute of Allergy and Infectious Disease...

Export this record

Export record to excel

Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206: Spero grants Pfizer rights to develop, manufacture, and commercialize SPR206 in ex-U.S....

Export this record

Export record to excel

Everest Medicines Announces Approval of Investigational New Drug Application by China NMPA for SPR206

Export this record

Export record to excel

Everest Medicines Announces Approval of Investigational New Drug Application by China NMPA for SPR206

Export this record

Export record to excel

Press Release: Everest Medicines Announces Approval of Investigational New Drug Application by China NMPA for SPR206

Export this record

Export record to excel

Everest Medicines: Spero Therapeutics, Pfizer In Deal For SPR206 In Ex-U.S. And Ex-Asia Territories

Export this record

Export record to excel

Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206

Refine your search